Volume : 11, Issue : 12, December – 2024
Title:
A REVIEW ON INNOVATIVE AND THERAPEUTIC STRATEGIES IN ALZHEIMER’S DISEASE.
Authors :
Mr.Chinthaparthi.Akhil Asif , Mrs.U.Nirupama, Dr.K.Venu gopal
Abstract :
Alzheimer’s disease is a progressive neurodegenerative disorder primarily affecting older adults, marked by memory loss, cognitive decline, and behavioral changes. As the global population ages, the prevalence of Alzheimer’s disease is increasing, straining healthcare systems and families. While current treatments like cholinesterase inhibitors (donepezil, rivastigmine, galantamine) help manage symptoms by improving neurotransmitter function, they do not halt disease progression. Research has shifted towards understanding the molecular mechanisms of Alzheimer’s disease, including amyloid-beta plaque accumulation, tau protein hyperphosphorylation, neuroinflammation, and synaptic dysfunction. Developing early diagnostic tools, such as blood biomarkers and neuroimaging techniques, to facilitate timely intervention, as well as exploring novel therapies targeting amyloid, tau, and neuroinflammation. Gene therapies, neuroprotective strategies, and regenerative medicine are being investigated to address the underlying causes of Alzheimer’s disease. Additionally, advancements in nanotechnology are enabling more precise drug delivery, overcoming challenges like the blood-brain barrier. Personalized medicine, integrating genetic and environmental factors, aims to optimize treatments for individual patients. Non-pharmacological interventions, such as cognitive and behavioral therapies, and lifestyle modifications like exercise, diet, and social engagement, are being explored to improve quality of life. Preventive strategies focusing on cardiovascular health, sleep hygiene, and stress management show promise in reducing Alzheimer’s disease risk. While no cure exists, a multi-faceted approach combining early detection, innovative treatments, and holistic care offers hope for slowing the progression of Alzheimer’s disease and enhancing the well-being of affected individuals and their caregivers.
Key Words: Alzheimer’s disease, Neurodegeneration, Amyloid-beta, Neuroinflammation, Early diagnosis, personalized medicine.
Cite This Article:
Please cite this article in press Chinthaparthi Akhil Asif et al A Review On Innovative And Therapeutic Strategies In Alzheimer’s Disease. .,Indo Am. J. P. Sci, 2024; 11 (12).
Number of Downloads : 10
References:
1. De-Paula V.J., Radanovic M., Diniz B.S., Forlenza O.V. Alzheimer’s disease. Sub-Cell. Biochem. 2012;65:329–352. doi: 10.1007/978-94-007-5416-4_14.
2. Cipriani G., Dolciotti C., Picchi L., Bonuccelli U. Alzheimer and his disease: A brief history. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2011;32:275–279. doi:10.1007/s10072-010-0454-7.
3. Blass J.P. Alzheimer’s disease. Dis. A Mon. Dm. 1985;31:1–69. doi: 10.1016/0011- 5029(85)90025-2.
4. Terry R.D., Davies P. Dementia of the Alzheimer type. Annu. Rev. Neurosci. 1980;3:77–95. doi: 10.1146/annurev.ne.03.030180.000453.
5. Rathmann K.L., Conner C.S. Alzheimer’s disease: Clinical features, pathogenesis, and treatment. Drug Intell. Clin.Pharm.1984;18:684–691. doi: 10.1177/106002808401800902.
6. Yiannopoulou K.G., Papageorgiou S.G. Current and future treatments in alzheimer disease: An update. J. Cent. Nerv. Syst. Dis. 2020:12. doi: 10.1177/1179573520907397.
7. Ahmad FB, Cisewski JA, Xu J, Anderson RN. Provisional Mortality Data – United States, 2022. MMWR Morb Mortal Wkly Rep. 2023 May 05;72(18):488-492.
8. Mendez MF. Early-Onset Alzheimer Disease. Neurol Clin. 2017 May;35(2):263-281.
9. Zetterberg H, Bendlin BB. Biomarkers for Alzheimer’s disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry. 2021 Jan;26(1):296-308.
10. Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021. J Prev Alzheimers Dis. 2021;8(3):371-386.
11. Therriault J, Zimmer ER, Benedet AL, Pascoal TA, Gauthier S, Rosa-Neto P. Staging of Alzheimer’s disease: past, present, and future perspectives. Trends Mol Med. 2022 Sep;28(9):726- 741.
12. Tang Y, Lutz MW, Xing Y. A systems-based model of Alzheimer’s disease. Alzheimers Dement. 2019 Jan;15(1):168-171.
13. Zilberzwige-Tal S, Gazit E. Go with the Flow-Microfluidics Approaches for Amyloid Research. Chem Asian J. 2018 Nov 16;13(22):3437-3447.
14. Maccioni RB, González A, Andrade V, Cortés N, Tapia JP, Guzmán-Martínez L. Alzheimer´s Disease in the Perspective of Neuroimmunology. Open Neurol J. 2018;12:50-56.
15. Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimers Dement (Amst). 2017;7:69-87.
16. Anjum I, Fayyaz M, Wajid A, Sohail W, Ali A. Does Obesity Increase the Risk of Dementia: A Literature Review. Cureus. 2018 May 21;10(5):e2660.
17. Paroni G, Bisceglia P, Seripa D. Understanding the Amyloid Hypothesis in Alzheimer’s Disease. J Alzheimers Dis. 2019;68(2):493-510.
18. Salehi A, Ashford JW, Mufson EJ. The Link between Alzheimer’s Disease and Down Syndrome. A Historical Perspective. Curr Alzheimer Res. 2016;13(1):2-6.
19. Hoogmartens J, Cacace R, Van Broeckhoven C. Insight into the genetic etiology of lzheimer’s disease: A comprehensive review of the role of rare variants. Alzheimers Dement (Amst).2021;13(1):e12155.
20. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189.